KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans.

Rosie Mngqibisa, Yashna Singh, Catherine Orrell, Johan Lombaard, Sandy Griffith, Conn Harrington, Ronald D'Amico, William Spreen, Marty St Clair, Christine Latham, Louise Garside, Rodica Van Solingen-Ristea, Veerle Van Eygen, Fafa Addo Boateng, Herta Crauwels, Prosperity Eneh, Ingrid Eshun-Wilsonova

South Afr J HIV Med 26(1) 1709

PMID40801059
PMCIDPMC12339864
DOI10.4102/sajhivmed.v26i1.1709
发表日期2025-08-13
摘要

摘要

BACKGROUND: Evaluating long-term efficacy, safety and pharmacokinetics of long-acting cabotegravir + rilpivirine (CAB+RPV LA) in sub-Saharan African populations is important because of the region's unique demographics and antiretroviral therapy resistance patterns. OBJECTIVES: To describe the 96-week efficacy, safety and pharmacokinetics of CAB+RPV LA in South African participants from the pooled FLAIR and ATLAS-2M Phase 3/3b randomised studies. METHOD: Primary endpoint: proportion of participants with plasma HIV-1 RNA levels ≥ 50 copies/mL at Week 96. Secondary endpoints: proportion of participants with plasma HIV-1 RNA levels < 50 copies/mL, confirmed virological failure (CVF; two consecutive plasma HIV-1 RNA ≥ 200 copies/mL), adverse events and pharmacokinetics. RESULTS: Sixty-six participants were included, (CAB+RPV LA, n = 49; current oral antiretroviral regimen [CAR], n = 17). Forty-five (92%) on CAB+RPV LA and 15 (88%) on CAR maintained HIV-1 RNA levels < 50 copies/mL. At Week 96, two participants, one in each arm, had CVF. Ninety per cent on CAB+RPV LA and 76% on CAR of participants experienced an adverse event; six (12%) of which were drug-related (CAB+RPV LA: n = 6). Injection-site reactions were common (78% [Grade 1: 80%; Grade 2: 20%]). CAB and RPV trough plasma concentrations remained above respective in vitro protein-adjusted 90% inhibitory concentrations following all doses. CONCLUSION: This subgroup analysis of South African participants demonstrated durable efficacy, acceptable safety profile and pharmacokinetics of injectable CAB+RPV LA up to 96 weeks, consistent with long-term data from other regions and studies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。